Boehringer Ingelheim and Optimum Patient Care are launching a new patient registry, APEX COPD (Advancing the Patient Experience in COPD), to better understan
The head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country that the company still regards it as an important market for new drug lau
Boehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, as price competition began to affect its biggest selling drug Spiriva.<
